Back to discover
Disease

Keratitis

Late-stage therapeutic developmentEmerging research
MeSHKeratitis
3
Publications
18
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
Results expected Q3 20272026-06-05
Upcoming trial readoutHigh impact
Parasitic Ulcer Treatment Trial
Results expected Q3 20292026-05-01
Clinical Milestones7View
Results posted 2
Results expected 3
Recently completed 2
Activity timeline7

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Polihexanideapproved

Approval — Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children… (2024)

Clinical trials

14 sponsors · 2 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

Parasitic Ulcer Treatment Trial

Phase 3 · Recruiting · Jeremy Keenan, MD, MPH

A Phase 4 Pilot Study With Extension to Assess the Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease and the Effect on Corneal Nerves and Neuropathic Corneal Pain

Phase 4 · Recruiting · Toyos Clinic

Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

Phase 3 · Recruiting · University of California, San Francisco

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II

Phase 3 · Active, not recruiting · University of California, San Francisco

TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment With Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis

Phase 4 · Active, not recruiting · Toyos Clinic

Steroids and Cross-linking for Ulcer Treatment

Phase 3 · Completed · Thomas M. Lietman
Recently completed

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Phase 3 · Completed · University of California, San Francisco

Steroids and Cross-linking for Ulcer Treatment

Phase 3 · Completed · Thomas M. Lietman

Evaluation of the Safety and Efficacy of Cyclosporine A 0.05% Eye Drops in Management of Non- Necrotizing Herpetic Stromal Keratitis; a Prospective Controlled Clinical Trial

Phase 4 · Completed · Farwaniya Hospital

A Phase IIIb, Prospective, Interventional, Multicentre, 3-year Study to Explore the Long-term Evolution of Sign and Symptoms, and Occurence of Complications in Dry Eye Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Phase 3 · Completed · Santen SAS

An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)

Phase 4 · Completed · Dompé Farmaceutici S.p.A

Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis

Phase 3 · Completed · SIFI SpA

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaApproval — Polihexanide· Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20232024
Major themes8
  • Keratitis2
  • Conjunctiva1
  • Cornea1
  • Corneal Ulcer1
  • Cytokines1
  • Eye Infections, Bacterial1
  • Photochemotherapy1
  • Photosensitizing Agents1
Leading journals3
  • Advanced materials (Deerfield Beach, Fla.)1
  • Frontiers in cellular and infection microbiology1
  • Indian journal of ophthalmology1
Leading researchers8
  • Alenezi H1
  • Ambastha A1
  • Arya LK1
  • Benson S1
  • Carnt N1
  • Duncan S1
  • Fingerhut L1
  • Jiang G1
Affiliations (unnormalised)6
  • Centre for Immunology and Allergy Research1
  • Centre for Inflammation Research1
  • Centre for Vision Research1
  • Department of Medical Laboratory Sciences1
  • Department of Microbiology Indira Gandhi Institute of Medical Sciences1
  • Institute for Regeneration and Repair1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Inflammation of the cornea.

Identifiers
MeSHKeratitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.